RecruitingNCT07070128

Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer

Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (STAR-BREAST)

Sponsor

AstraZeneca

Enrollment

800 participants

Start Date

Aug 20, 2025

Study Type

OBSERVATIONAL

Conditions

Breast Neoplasms

Summary

It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.

Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This study tests whether an AI tool can accurately predict which women are at high genetic risk for breast cancer, comparing it against traditional genetic counseling assessments. The goal is to see if artificial intelligence can help identify women who should be tested for inherited breast cancer genes (like BRCA1 and BRCA2). **You may be eligible if...** - You are a woman aged 18 or older - Your surgeon has identified you as high risk for genetic breast cancer - You have been referred to a geneticist - You agree to participate in the study **You may NOT be eligible if...** - You are male - Your medical records are incomplete - You have already been identified as not meeting criteria for genetic testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.